

ALLERGAN INC  
Form SC 14D9/A  
July 24, 2014

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14D-9**

**SOLICITATION/RECOMMENDATION**

**STATEMENT UNDER SECTION 14(d)(4) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**(AMENDMENT NO. 14)**

**Allergan, Inc.**

*(Name of Subject Company)*

**Allergan, Inc.**

*(Name of Person Filing Statement)*

**Common Stock, \$0.01 par value**

*(Title of Class of Securities)*

**018490102**

*(CUSIP Number of Class of Securities)*

**Matthew J. Maletta, Esq.**

**Vice President,**

**Associate General Counsel and Secretary**

**2525 Dupont Drive**

**Irvine, California 92612**

**(714) 246-4500**

(Name, address and telephone number of person authorized to receive notices and communications on behalf of the person filing statement)

*With copies to:*

**Paul D. Tosetti, Esq.**

**Cary K. Hyden, Esq.**

**Michael A. Treska, Esq.**

**Latham & Watkins LLP**

**650 Town Center Drive, 20th Floor**

**Costa Mesa, California 92626**

**(714) 540-1235**

**David A. Katz, Esq.**

**Daniel A. Neff, Esq.**

**Wachtell, Lipton, Rosen & Katz**

**51 West 52nd Street**

**New York, New York 10019**

**(212) 403-1000**

.. Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Amendment No. 14 to Schedule 14D-9 amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended from time to time, the *Statement* ) originally filed by Allergan, Inc., a Delaware corporation ( *Allergan* ), with the Securities and Exchange Commission (the *SEC* ) on June 23, 2014, as last amended by Amendment No. 13, filed with the SEC on July 21, 2014, relating to the unsolicited offer by Valeant Pharmaceuticals International, Inc., a corporation continued under the laws of the Province of British Columbia ( *Valeant* ), through its wholly owned subsidiary, AGMS Inc., a Delaware corporation, to exchange each outstanding share of Allergan's common stock, par value \$0.01 per share (including the associated preferred stock purchase rights, the *Shares* ), at the election of the holder of the Shares, for either 0.83 common shares of Valeant, no par value (the *Valeant Common Shares* ), and \$72.00 in cash, or an equal amount of cash or number of Valeant Common Shares, upon the terms and subject to the election and proration procedures and other conditions set forth in its Preliminary Prospectus/Offer to Exchange, dated June 18, 2014 (as amended or supplemented from time to time), and the related letter of election and transmittal. Except as specifically noted herein, the information set forth in the Statement remains unchanged. This Amendment is being filed to reflect certain updates as reflected below:

**ITEM 9. EXHIBITS.**

Item 9 of the Statement is hereby amended and supplemented by adding the following exhibits:

- (a)(26) Description of performance vesting criteria to certain non-qualified stock options to be granted to select employees in the first quarter of 2015 (incorporated by reference to Item 8.01 of the Current Report on Form 8-K filed with the SEC on July 23, 2014)
- (a)(27) Allergan, Inc. investor presentation dated July 23, 2014 (incorporated by reference to the Schedule 14A filed with the  
  
SEC by Allergan on July 23, 2014)

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

**ALLERGAN, INC.**

By: /s/ Matthew J. Maletta

Name: Matthew J. Maletta

Title: Vice President,

Associate General Counsel and Secretary

Dated: July 23, 2014

**Exhibit Index**

<b>Exhibit</b>	<b>Description of Exhibit</b>
(a)(26)	Description of performance vesting criteria to certain non-qualified stock options to be granted to select employees in the first quarter of 2015 (incorporated by reference to Item 8.01 of the Current Report on Form 8-K filed with the SEC on July 23, 2014)
(a)(27)	Allergan, Inc. investor presentation dated July 23, 2014 (incorporated by reference to the Schedule 14A filed with the  SEC by Allergan on July 23, 2014)